Relief Therapeutics Financials
| RLF Stock | CHF 5.00 0.06 1.21% |
Relief |
Please note, the imprecision that can be found in Relief Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Relief Therapeutics Holding. Check Relief Therapeutics' Beneish M Score to see the likelihood of Relief Therapeutics' management manipulating its earnings.
Relief Therapeutics Stock Summary
Relief Therapeutics competes with VAT Group, Lonza Group, Basilea Pharmaceutica, Straumann Holding, and Santhera Pharmaceuticals. Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company was founded in 2013 and is based in Geneva, Switzerland. RELIEF THERAPEUTICS operates under Pharmaceuticals And Biosciences classification in Switzerland and is traded on Switzerland Exchange. It employs 10 people.| Foreign Associate | USA |
| Instrument | Switzerland Stock View All |
| Exchange | SIX Swiss Exchange |
| ISIN | CH0100191136 |
| Business Address | BAtiment F2F3, Geneva, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.relieftherapeutics.com |
| Phone | 41 44 723 59 59 |
| Currency | CHF - Swiss Franc |
You should never invest in Relief Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Relief Stock, because this is throwing your money away. Analyzing the key information contained in Relief Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Relief Therapeutics Key Financial Ratios
There are many critical financial ratios that Relief Therapeutics' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Relief Therapeutics reports annually and quarterly.| Return On Equity | -0.33 | |||
| Return On Asset | -0.12 | |||
| Number Of Employees | 10 | |||
| Beta | -13.71 |
Relief Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Relief Therapeutics's current stock value. Our valuation model uses many indicators to compare Relief Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Relief Therapeutics competition to find correlations between indicators driving Relief Therapeutics's intrinsic value. More Info.Relief Therapeutics Holding is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Relief Therapeutics' earnings, one of the primary drivers of an investment's value.Relief Therapeutics Systematic Risk
Relief Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Relief Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Relief Therapeutics correlated with the market. If Beta is less than 0 Relief Therapeutics generally moves in the opposite direction as compared to the market. If Relief Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Relief Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Relief Therapeutics is generally in the same direction as the market. If Beta > 1 Relief Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Relief Therapeutics December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Relief Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Relief Therapeutics Holding. We use our internally-developed statistical techniques to arrive at the intrinsic value of Relief Therapeutics Holding based on widely used predictive technical indicators. In general, we focus on analyzing Relief Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Relief Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 7.56 | |||
| Information Ratio | 0.2189 | |||
| Maximum Drawdown | 75.45 | |||
| Value At Risk | (10.64) | |||
| Potential Upside | 23.15 |
Additional Tools for Relief Stock Analysis
When running Relief Therapeutics' price analysis, check to measure Relief Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relief Therapeutics is operating at the current time. Most of Relief Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relief Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relief Therapeutics' price. Additionally, you may evaluate how the addition of Relief Therapeutics to your portfolios can decrease your overall portfolio volatility.